A.R. Lavik1, N.-H. Yayah Jones1, S. Rompicherla2, M. Greenfield3, J. Chen3, S. Polsky4, G.T. Alonso4, S. Corathers1, S. Blackman5, M.P. Gallagher6, C. Demeterco-Berggren7, A. Garrity8, O. Ebekozien2

1Cincinnati Children’s Hospital Medical Center, Cincinnati, USA, 2T1D Exchange, Boston, USA, 3SUNY Upstate Medical University, Syracuse, USA, 4Barbara Davis Center for Diabetes, Aurora, USA, 5Johns Hopkins Hospital, Baltimore, USA, 6NYU Langone, New York, USA, 7Rady Children’s Hospital, San Diego, USA, 8University of Michigan CS Mott Children’s Hospital, Ann Arbor, USA

Introduction: The COVID-19 pandemic has had far-reaching consequences for individuals with type 1 diabetes (T1D) and has laid bare inequities in health care.

Objectives: We sought to examine the United States (US) trends in diabetic ketoacidosis (DKA) across the lifespan during the COVID-19 pandemic and factors associated with these trends, compared to DKA rates the year prior to the pandemic.

Methods: The T1D Exchange Quality Improvement Collaborative (T1DX-QI) collected aggregate data on the incidence of DKA among children and adults with established and new-onset T1D from 7 large medical centers in the US (total T1D population >15,000). We compared DKA rates during COVID-19 Wave 1 (March-May 2020) and COVID-19 Wave 2 (August-October 2020) to the same periods in 2019. Descriptive statistics were used to summarize data. Chi-square tests were used to compare differences in patient characteristics.

Click here to read the full abstract